BioAgilytix Acquires Australian-Based CRO 360biolabs

BioAgilytix, a US-based contract research laboratory focused on large-molecule drug development, has agreed to purchase 360biolabs, an Australia-based contract research organization specializing in virology and immunology.

This agreement, signed on Aug. 16, 2021, will allow BioAgilytix to expand their first-in-human trial and early phase clinical trials into a new jurisdiction. Under the agreement, 360biolabs' facilities in Melbourne, Victoria, will be added to BioAgilytix’s existing laboratories in Durham, NC, Boston, Mass., and Hamburg, Germany.

The new facilities feature biosafety level 2 and three laboratories, a flow cytometry suite, a molecular biology polymerase chain reaction suite, and liquid chromatography–mass spectrometry/mass-spectrometry small-molecule capabilities.

"This planned acquisition is part of our strategic growth strategy to expand our capacity, expertise, and agility to serve customers across all geographies, and we look forward to welcoming the 360biolabs team and integrating the business," said Jim Datin, president and CEO of BioAgilytix, in a company press release. "Joining forces makes sense for our two organizations, but most importantly for our combined clients and the patients they serve. BioAgilytix and 360biolabs are already culturally aligned in our focus on doing science right, on time, the first time. Together, we will not only create significant scientific synergies but also generate new innovations and help bring future life-changing therapeutics to patients more rapidly around the globe."

Source: BioAgilytix